Skip Nav Destination
Issues
1 June 2023
-
Cover Image
Cover Image
The cover shows a section of a tumor needle biopsy from a patient with urothelial carcinoma treated with guadecitabine and atezolizumab. Hematoxylin and eosin immunohistochemical staining reveals the tumor and stromal architecture of the urothelial carcinoma. For details, see the article by Jang and colleagues on page 2052 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor
Vaibhav Kumar; Leslie Doros; Margaret Thompson; Sirisha L. Mushti; Rosane Charlab; Elizabeth I. Spehalski; Hong Zhao; Matthew D. Thompson; Shenghui Tang; Richard Pazdur; Steven J. Lemery; Marc R. Theoret; Lola A. Fashoyin-Aje
Review
Clinical Trials: Targeted Therapy
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Amir T. Fathi; Haesook T. Kim; Robert J. Soiffer; Mark J. Levis; Shuli Li; Annette S. Kim; Zachariah DeFilipp; Areej El-Jawahri; Steve L. McAfee; Andrew M. Brunner; Philip C. Amrein; Alice S. Mims; Laura W. Knight; Devon Kelley; AJ S. Bottoms; Lindsey H. Perry; Jonathan L. Wahl; Jennifer Brock; Elayne Breton; Dylan M. Marchione; Vincent T. Ho; Yi-Bin Chen
Clinical Trials: Immunotherapy
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Ciara M. Kelly; Li-Xuan Qin; Karissa A. Whiting; Allison L. Richards; Viswatej Avutu; Jason E. Chan; Ping Chi; Mark A. Dickson; Mrinal M. Gounder; Mary Louise Keohan; Sujana Movva; Benjamin A. Nacev; Evan Rosenbaum; Travis Adamson; Samuel Singer; Edmund K. Bartlett; Aimee M. Crago; Sam S. Yoon; Sinchun Hwang; Joseph P. Erinjeri; Cristina R. Antonescu; William D. Tap; Sandra P. D'Angelo
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
H. Josh Jang; Galen Hostetter; Alexander W. Macfarlane; Zachary Madaj; Eric A. Ross; Toshinori Hinoue; Justin R. Kulchycki; Ryan S. Burgos; Mahvish Tafseer; R. Katherine Alpaugh; Candice L. Schwebel; Rutika Kokate; Daniel M. Geynisman; Matthew R. Zibelman; Pooja Ghatalia; Peter W. Nichols; Woonbok Chung; Jozef Madzo; Noah M. Hahn; David I. Quinn; Jean-Pierre J. Issa; Michael J. Topper; Stephen B. Baylin; Hui Shen; Kerry S. Campbell; Peter A. Jones; Elizabeth R. Plimack
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith; Weimin Li; Song Wu; Ross Stewart; Nassim Morsli; Rajiv Raja; Qu Zhang; Jiabu Ye; Philip He; Jagdish Shetty; Alejandro Yovine; Nicholas Holoweckyj; Katia Real; Jill Walker; Magdalena Wrona; Melissa de los Reyes; Craig Barker; Jessica Whiteley; Robert Haddad; Lisa Licitra; Robert Ferris; Jérôme Fayette; Dan P. Zandberg; Lillian L. Siu; Ricard Mesía
Precision Medicine and Imaging
[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Ramsha Iqbal; Maqsood Yaqub; Huseyyin O. Bektas; Daniela E. Oprea-Lager; Elisabeth G.E. de Vries; Andor W.J.M. Glaudemans; Philippe Aftimos; Géraldine Gebhart; Andrew P. Beelen; Robert C. Schuit; Albert D. Windhorst; Ronald Boellaard; C. Willemien Menke-van der Houven van Oordt
Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients
Sasimol Udomruk; Areerak Phanphaisarn; Thanat Kanthawang; Apiwat Sangphukieo; Songphon Sutthitthasakul; Siripong Tongjai; Pimpisa Teeyakasem; Patcharawadee Thongkumkoon; Santhasiri Orrapin; Sutpirat Moonmuang; Jeerawan Klangjorhor; Arnat Pasena; Pathacha Suksakit; Sivamoke Dissook; Pitithat Puranachot; Jongkolnee Settakorn; Tonapha Pusadee; Dumnoensun Pruksakorn; Parunya Chaiyawat
Translational Cancer Mechanisms and Therapy
Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas
Jordan A. Stinson; Allison Sheen; Noor Momin; Jordan Hampel; Rebecca Bernstein; Rebecca Kamerer; Bahaa Fadl-Alla; Jonathan Samuelson; Elizabeth Fink; Timothy M. Fan; K. Dane Wittrup
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Michael J. Grant; Jacqueline V. Aredo; Jacqueline H. Starrett; Paul Stockhammer; Iris K. van Alderwerelt van Rosenburgh; Anna Wurtz; Andrew J. Piper-Valillo; Zofia Piotrowska; Christina Falcon; Helena A. Yu; Charu Aggarwal; Dylan Scholes; Tejas Patil; Christina Nguyen; Manali Phadke; Fang-Yong Li; Joel Neal; Mark A. Lemmon; Zenta Walther; Katerina Politi; Sarah B. Goldberg
Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Martina S.J. McDermott; Neil A. O'Brien; Benjamin Hoffstrom; KeWei Gong; Ming Lu; Jun Zhang; Tong Luo; Min Liang; Weiping Jia; Jenny J. Hong; Kevin Chau; Simon Davenport; Bin Xie; Michael F. Press; Richard Panayiotou; Abram Handly-Santana; Joan S. Brugge; Leonard Presta; John Glaspy; Dennis J. Slamon
Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor
Ferdinand Rossi; Mengyuan Liu; Andrew Tieniber; Mark S. Etherington; Andrew Hanna; Gerardo A. Vitiello; Nesteene J. Param; Kevin Do; Laura Wang; Cristina R. Antonescu; Shan Zeng; Jennifer Q. Zhang; Ronald P. DeMatteo
G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
Anita L. Ray; Apryl S. Saunders; Robert A. Nofchissey; Megan A. Reidy; Maria Kamal; Megan R. Lerner; Kar-Ming Fung; Mark L. Lang; Joshua A. Hanson; Shaoxuan Guo; Maria G. Urdaneta-Perez; Samara E. Lewis; Michael Cloyde; Katherine T. Morris
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds